EGON-ZEHNDER
11.6.2019 09:02:08 CEST | Business Wire | Press release
A global study of the first generation of Chief Digital Officers has found that evolving company culture is proving a significant challenge, with the majority (54%) spending more time evangelizing within their business than executing their digital strategy.
Egon Zehnder, the world’s leadership consulting firm, surveyed CDOs in large companies across 20 countries globally, whose combined revenues total $1 trillion, to explore their expectations and experiences and identify the actions leaders should take to accelerate digital transformation within their organizations.
The study, CDO Decoded: The First Wave of CDOs Speaks , also shows there is still little shared understanding of the role and responsibilities of a CDO. While lines of reporting and key responsibilities vary widely, what unites this group is their pioneering status - the overwhelming majority are the first to hold this role in their organization.
“Organizations and - it turns out - CDOs themselves are still working out what it means to be the CDO,” said Lindsay Trout, Global Digital Practice Leader at Egon Zehnder. “It’s clear though that the experiences of this first generation will shape the direction businesses take in the future.”
CDOs also questioned whether a digital-only role will become obsolete over time. Rob Barger, CDO of Georgia-Pacific, said: “I should not exist in this role in five years.”
Key research findings
The challenges of culture change
- While just 10% of CDOs saw their primary role as evolving company culture, 54% said they spend more time on evangelizing than executing.
- 80% of respondents found that evolving company culture was either more difficult or much more difficult than they expected. 68% also cited integration of data and breaking down silos.
- Just 25% CDOs thought their organizations were ready for digital transformation when they were first hired.
- Executive commitment and company culture were cited as the two most critical factors in achieving digital transformation by 58% and 57% of CDOs, respectively.
Who today’s CDOs are
- This is a group of pioneers - 84% are the first to hold a CDO role in their organization and 65% have been in the role for three years or less.
- CDO is a senior role - 63% report directly to the CEO.
The confidence and ambitions of CDOs
- 42% of CDOs believe their next job would be a CEO role.
- 50% said the scope of impact was their primary reason for taking on the CDO role.
Recommendations
Egon Zehnder recommends several actions to ensure the success of a CDO, including:
- Hire evangelists AND executors: If internal culture change will be required, choose a CDO capable of rallying teams and expressing a vision.
- Make sure the C-suite gets it: The CEO must ensure the C-suite, including the CFO as well as other P&L leaders, understands the CDO role and supports investment in digital transformation.
- Don’t forget about culture: Nothing happens without organizational buy-in.
- Give the CDO freedom to build a strong team : Many CDOs build teams that are a combination of new talent and expertise and legacy.
- Be willing to measure success in different ways: The CDO must have the right to develop and use their own benchmarks, even in parts of the business that they are not in charge of.
Further information
To read the full CDO Decoded report visit www.egonzehnder.com/cdo-decoded
NOTES TO EDITORS
About the 2019 CDO Survey
Egon Zehnder conducted in-depth surveys with 107 CDOs in 20 countries during December 2018.
About Egon Zehnder
Egon Zehnder is the world’s leadership consulting firm, sharing one goal: to transform people, organizations and the world through great leadership.
We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients.
As One Firm, our more than 480 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team.
We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.
We offer a range of integrated services to support our leadership consulting work, such as: our investment in Zurich, Switzerland-based Sinequanon (SQN), a firm that uses AI and advanced analytics to improve workplace culture and performance, and our strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA based leadership development firm, which delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing.” In addition, we have partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.
We share a commitment and pride in doing work that contributes to successful careers, stronger companies and a better world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005042/en/
Contact:
Media: Jennifer Reingold Global Head of Content P: +1 212-519-6286 Stacy Drumtra US Head of Marketing and Communications P: +1 312-260-8974
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
